Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Among the antithrombotic therapies evaluated to date, the synthetic peptide bivalirudin is unique in its ability to reduce both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is a small peptide consisting of 20 amino acid residues that binds thrombin in a direct, reversible, and bivalent fashion. The agent is approved for use in the United States and New Zealand as an anticoagulant in patients with unstable angina undergoing PCI and may also prove beneficial in patients with acute coronary syndromes (ACS), acute myocardial infarction (AMI) and in patients undergoing coronary artery bypass graft (CABG) procedures. This article examines bivalirudin in more detail.

Original languageEnglish
Pages (from-to)142-148
Number of pages7
JournalHamostaseologie
Volume22
Issue number3
DOIs
Publication statusPublished - 2002
Externally publishedYes

Keywords

  • Anticoagulant
  • Bivalirudin
  • Percutaneous coronary intervention
  • Thrombia inhibitor
  • Unstable angina

Fingerprint Dive into the research topics of 'Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures'. Together they form a unique fingerprint.

  • Cite this